[The effect of antiaggregants on the course of diabetic microangiopathy].
As shown by conjunctival biomicroscopy, 6-month administration of ticlid and gliclazide induced a statistically significant increase in the frequency of less severe microcirculatory disturbances compared to conventional hypoglycemic therapy. The drugs also restricted plasmatic impregnation and cell proliferation in skin biopsy microvascular wall. Following 2-year antiaggregation treatment (gliclazide, trental, dipiridomol) 48.9% of diabetes mellitus patients achieved regression of morphological manifestations of diabetic microangiopathy, 16.2% stabilization against 34.9% of progressive disease cases. Conventional sugar-reducing therapy fails to stop diabetic microangiopathy progression in 73.4-93.3% of the diabetics.
Bokarev
I N
IN
Velikov
V K
VK
Zelenchuk
N M
NM
Shubina
O I
OI
Saltykov
B B
BB
Frolova
A I
AI
Polunin
G S
GS
Pirogova
E P
EP
Nikol'skaia
V V
VV
Davydova
N G
NG
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000503:physiopathology; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000503:physiopathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012867:Skin / Q000098:blood supply
D010975:Platelet Aggregation Inhibitors
Vliianie antiagregantov na techenie diabeticheskoĭ mikroangiopatii.